الــ FDA ستجتمع مع خبراء الشركة بتاريخ
January 13 and 14, 2005, in Washington, D.C
لمناقشة امكانية تسويق منتج الشركة بدون قيود طبية
وامكانية الحصول على المنتج من اي مكان لبيع التجزيئه
اذا تمت الموافقه فان الشركة تتوقع ازدياد فرص تسويق المنتج
the FDA has agreed to hear a major pharmaceutical company's petition to move its statin drug from a prescriptive to a non-prescriptive status at retail stores," said Christopher Maus, Lifestream's CEO. "In a previous hearing, the FDA comments addressed the consumer's ability to know and track their cholesterol number. If the FDA finds that this statin drug is suitable for non-prescriptive consumer use, Lifestream sees a significant opportunity that could open the floodgates for monitoring cholesterol at home or at the point of care. This increased awareness for regular monitoring would be most conducive in supporting all cholesterol lowering programs through positive feedback and, thus, the greater likelihood of compliance
http://biz.yahoo.com/bw/050106/65292_1.html
LAST = 0.03